HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sutee Yoksan Selected Research

Biological Products

7/2014Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation.
2/2010A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sutee Yoksan Research Topics

Disease

37Dengue (Dengue Fever)
01/2021 - 01/2002
31Infections
12/2022 - 09/2004
23Japanese Encephalitis
12/2022 - 01/2002
7Severe Dengue
10/2019 - 05/2005
5Fever (Fevers)
01/2020 - 01/2008
4Viremia
10/2013 - 01/2002
3Yellow Fever
03/2006 - 01/2002
2Measles
08/2014 - 04/2008
1Vaccine-Preventable Diseases
01/2021
1Smallpox (Variola)
07/2020
1Poliomyelitis (Polio)
07/2020
1Virus Diseases (Viral Diseases)
01/2020
1Rabies (Hydrophobia)
01/2020
1Chikungunya Fever
02/2015
1Coinfection
07/2014
1Necrosis
05/2013
1Anemia
03/2012
1Hemorrhage
03/2012
1Arbovirus Infections
02/2010
1Flavivirus Infections
01/2002

Drug/Important Bio-Agent (IBA)

30VaccinesIBA
12/2022 - 01/2002
11Neutralizing AntibodiesIBA
01/2021 - 03/2002
10AntibodiesIBA
12/2014 - 09/2003
8Immunoglobulin G (IgG)IBA
01/2021 - 09/2003
8Proteins (Proteins, Gene)FDA Link
07/2020 - 01/2002
8Dengue VaccinesIBA
10/2019 - 09/2003
7AntigensIBA
02/2016 - 10/2003
6Immunoglobulin M (IgM)IBA
01/2021 - 12/2009
6EnzymesIBA
10/2019 - 10/2006
4ImmunosorbentsIBA
10/2019 - 10/2006
4Attenuated VaccinesIBA
10/2015 - 01/2002
3CytokinesIBA
01/2015 - 12/2012
2Viral RNAIBA
01/2021 - 09/2006
2Orlistat (Xenical)FDA Link
01/2020 - 01/2017
2Monoclonal AntibodiesIBA
10/2019 - 02/2015
2Antiviral Agents (Antivirals)IBA
12/2015 - 12/2010
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2015 - 12/2014
2Viral AntigensIBA
01/2015 - 12/2009
2Measles VaccineIBA
08/2014 - 04/2008
2Biological ProductsIBA
07/2014 - 02/2010
2ChimeriVaxIBA
10/2003 - 01/2002
1PolymersIBA
07/2021
1maleimideIBA
07/2021
1ChitosanIBA
07/2021
1Edetic Acid (EDTA)FDA Link
01/2020
1Rabies Vaccines (Rabies Vaccine)FDA Link
01/2020
1Japanese Encephalitis VaccinesIBA
01/2020
1Small Interfering RNA (siRNA)IBA
01/2017
1LipidsIBA
01/2017
1Fatty Acid Synthases (Fatty Acid Synthase)IBA
01/2017
1Fatty Acids (Saturated Fatty Acids)IBA
01/2017
1EpitopesIBA
01/2016
1InterferonsIBA
12/2015
1InterleukinsIBA
01/2015
1Caspase 8 (Caspase-8)IBA
12/2014
1ChemokinesIBA
12/2012
1isothiocyanic acidIBA
12/2009
1Fluorescein (Funduscein)FDA LinkGeneric
12/2009
1Viral ProteinsIBA
01/2009
1ThrombomodulinIBA
10/2006
1Broadly Neutralizing AntibodiesIBA
03/2006
1Intercellular Adhesion Molecule-3IBA
05/2005
1P-2 (P 2)IBA
05/2005

Therapy/Procedure

1Hematopoietic Stem Cell Transplantation
01/2021
1Drug Therapy (Chemotherapy)
03/2012
1Highly Active Antiretroviral Therapy (HAART)
11/2007